Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2014

01-02-2014 | short review

Multi-gene signatures in breast cancer: actual clinical impact

Authors: Simon P. Gampenrieder, MD, Gabriel Rinnerthaler, MD, Richard Greil, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2014

Login to get access

Abstract

The molecular pathology has fundamentally modified our understanding of breast cancer. Today, breast cancer is understood as a heterogeneous disease consisting of at least five different subtypes. These subtypes show specific mRNA levels and somatic alterations and derive probably from different precursor cells. Multi-gene signatures enable us not only to differentiate these subtypes but also to define different risk groups for relapse after primary treatment. The clinical impact of these signatures is critically discussed in this review.
Literature
1.
Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011 Oct;121(10):3810–8. PubMed PMID: 21965338. Pubmed Central PMCID: 3195464. Epub 2011/10/04. eng.
2.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747–52. PubMed PMID: 10963602. Epub 2000/08/30. eng.
3.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869–74. PubMed PMID: 11553815. Pubmed Central PMCID: 58566. Epub 2001/09/13. eng.
4.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009 Mar 10;27(8):1160–7. PubMed PMID: 19204204. Pubmed Central PMCID: 2667820. Epub 2009/02/11. eng.
5.
Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011 Feb;5(1):5–23. PubMed PMID: 21147047. Epub 2010/12/15. eng.
6.
Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res. 2012 Apr 15;18(8):2402–12. PubMed PMID: 22351696. Epub 2012/02/22. eng.
7.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncolcol. 2011 Aug;22(8):1736–47. PubMed PMID: 21709140. Pubmed Central PMCID: 3144634. Epub 2011/06/29. eng.
8.
Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst. 2012 Feb 22;104(4):311–25. PubMed PMID: 22262870. Pubmed Central PMCID: 3283537. Epub 2012/01/21. eng.
9.
Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013 Jan 10;31(2):203–9. PubMed PMID: 23233704. Pubmed Central PMCID: 3532392. Epub 2012/12/13. eng.
10.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep;24(9):2206–23. PubMed PMID: 23917950. Pubmed Central PMCID: 3755334. Epub 2013/08/07. eng.
11.
Nielsen TO, Polley MY-C, Leung SCY, Mastropasqua MG, Zabaglo LA, Bartlett JMS, et al. An international Ki67 reproducibility study. Cancer Res. 2012;72(24 Suppl.):Abstr. S4–6.
12.
Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011 May 24;104(11):1762–9. PubMed PMID: 21559019. Pubmed Central PMCID: 3111159. Epub 2011/05/12. eng.
13.
Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013 Aug 1;19(15):4196–205. PubMed PMID: 23757354. Epub 2013/06/13. eng.
14.
Drukker CA, Bueno-de-Mesquita JM, Retel VP, van Harten WH, van Tinteren H, Wesseling J, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013 Aug 15;133(4):929–36. PubMed PMID: 23371464. Epub 2013/02/02. eng.
15.
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013 Oct;14(11):1067–76. PubMed PMID: 24035531. Epub 2013/09/17. eng.
16.
Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, et al. The EndoPredict score identifies late distant metastases in ER+/HER2− breast cancer patients. Cancer Res. 2012;72(24 Suppl. 3):Abstr. S4–3.
17.
Gnant M, Filipits M, Dubsky P, Rudas M, Balic M, Greil R, et al. Predicting risk for late metastasis: the PAM50 Risk of Recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial. Ann Oncol. 2013;24(Suppl. 3):Abstr. 53O_PR:iii29.
18.
Italiano A. Prognostic or predictive? It’s time to get back to definitions! J Clin Oncol. 2011 Dec 10;29(35):4718. Author reply 4719. PubMed PMID: 22042948. Epub 2011/11/02. eng.
19.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 Aug 10;24(23):3726–34. PubMed PMID: 16720680. Epub 2006/05/25. eng.
20.
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan;11(1):55–65. PubMed PMID: 20005174. Pubmed Central PMCID: 3058239. Epub 2009/12/17. eng.
21.
Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009 Jan;11(1):3–14. PubMed PMID: 18813139. Pubmed Central PMCID: 2743609. Epub 2008/09/25. eng.
22.
Azim HA Jr, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group Consensus Statement. Ann Oncol. 2013 Mar;24(3):647–54. PubMed PMID: 23337633. Epub 2013/01/23. eng.
23.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20;25(33):5287–312. PubMed PMID: 17954709. Epub 2007/10/24. eng.
24.
Cardoso F, Kyriakides S, Penault-Llorca F, Poortmans P, Senkus E, Thompson A, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi7–vi23.
25.
National Institute for Health and Care Excellence (NICE): DG10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: guidance 2013. Updated 26 September 2013. http://​www.​nice.​org.​uk/​dg10. Accessed: Dec. 2013.
Metadata
Title
Multi-gene signatures in breast cancer: actual clinical impact
Authors
Simon P. Gampenrieder, MD
Gabriel Rinnerthaler, MD
Richard Greil, MD
Publication date
01-02-2014
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2014
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0130-3

Other articles of this Issue 1/2014

memo - Magazine of European Medical Oncology 1/2014 Go to the issue

case report

Case report of nab-paclitaxel in metastatic pancreatic cancer

short review

Treatment and clinical results in childhood AML in Greece

short review

Breast cancer surveillance: nothing has changed in the past decades (?)

short review

Lung cancer screening with low-dose computed tomography

short review

Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010

short review

Antibody–cytotoxic drug conjugates in clinical trials and future perspectives: the development of Trojan horses
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits